8 Result(s)
-
Article
Open AccessDecipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance
We aimed to validate Decipher to predict adverse pathology (AP) at radical prostatectomy (RP) in men with National Comprehensive Cancer Network (NCCN) favorable-intermediate risk (F-IR) prostate cancer (PCa), ...
-
Article
Open AccessSurvival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry
African Americans experience greater prostate cancer risk and mortality than do Caucasians. An analysis of pooled phase III data suggested differences in overall survival (OS) between African American and Cauc...
-
Article
Open AccessActive surveillance in intermediate-risk prostate cancer with PSA 10–20 ng/mL: pathological outcome analysis of a population-level database
Active surveillance (AS) is generally recognized as the preferred option for men with low-risk prostate cancer. Current guidelines use prostate-specific antigen (PSA) of 10–20 ng/mL or low-volume biopsy Gleaso...
-
Article
Correction to: Association between adherence to radiation therapy quality metrics and patient reported outcomes in prostate cancer
-
Article
The state of focal therapy in the treatment of prostate cancer: the university of California collaborative (UC-Squared) consensus statement
-
Article
Correction to: Prostate volume, baseline urinary function, and their association with treatment choice and post-treatment urinary function in men treated for localized prostate cancer
-
Article
Open AccessThe natural history of a delayed detectable PSA after radical prostatectomy
Men with a detectable PSA after radical prostatectomy (RP) are often offered salvage therapy while those with an undetectable PSA are monitored. We aim to better characterize the natural history of men with an...
-
Article
Open AccessPatient and physician perspectives on treatments for low-risk prostate cancer: a qualitative study
Patients diagnosed with low-risk prostate cancer (PCa) are confronted with a difficult decision regarding whether to undergo definitive treatment or to pursue an active surveillance protocol. This is potential...
